Table 4.

Best Overall Response (%) in Pivotal Phase 3 Trial of Ipilimumab in Patients With Previously Treated, Unresectable Advanced Melanoma

	Ipilimumab Alone (n = 137)	Ipilimumab + gp100 Vaccine (n = 403)	gp100 Vaccine Alone (n = 136)
Complete response	1.5	0.2	0
Partial response	9.5	5.5	1.5
Stable disease	17.5	14.4	9.6
Progressive disease	51.1	59.3	65.4
Not evaluated	20.4	20.6	23.5

gp100 = glycoprotein 100.

Data based on text from Hodi FS, O’Day SJ, McDermott DF, et al. N Engl J Med 2010;363:211–223.²⁵